KaloBios Pharmaceuticals Inc. (HGEN)
(Delayed Data from OTC)
$1.15 USD
-0.07 (-6.07%)
Updated May 3, 2019 01:59 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HGEN 1.15 -0.07(-6.07%)
Will HGEN be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HGEN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HGEN
Humanigen (HGEN) Surges on Lenzilumab Study Data for Leukemia
Rapt Therapeutics (RAPT) Reports Q3 Loss, Lags Revenue Estimates
HGEN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Misses Revenue Estimates
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Surpass Estimates